Roivant Sciences Ltd.

ROIV Nasdaq SEC CIK 1635088
Follow Roivant Sciences Ltd. Weekly email: filings, results

Financials

Reported figures only · latest: Q2 2027 USD · US GAAP
Revenue, last quarter $35.1M +2135.6% vs same quarter last year
Net income −$191.6M −68.8% vs same quarter last year
EPS, diluted −$0.27 −58.8% vs same quarter last year
Operating cash flow $594.4M +420.2% vs same quarter last year
Revenue by quarter
$9M
$7.6M
$2.2M
$1.6M
$2M
$2.5M
$1.4M
$35.1M
Q3 25 Q4 25 Q1 26 Q2 26 Q3 26 Q4 26 Q1 27 Q2 27

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income7 fiscal years
  • Revenue
  • Net income
−$2B$0$2B$4B$6BFY20FY21FY22FY23FY24FY25FY26
Show the numbers
YearRevenueNet income
FY26$8.3M−$299.8M
FY25$29.1M−$172M
FY24$32.7M$4.3B
FY23$31.5M−$1B
FY22$55.3M−$845.3M
FY21$23.8M−$809.2M
FY20--
MarginsShare of revenue
  • Operating margin
  • Net margin
−10000%−5000%0%5000%10000%15000%FY20FY21FY22FY23FY24FY25FY26
Show the numbers
YearOperating marginNet margin
FY26−6235.7%−3629.2%
FY25−3453.3%−592%
FY2413746.9%13294.2%
FY23−2875.9%−3200.2%
FY22−2444.8%−1528.9%
FY21−4500.5%−3400.9%
FY20--
Free cash flowOperating cash flow minus capital expenditure
−$1B−$750M−$500M−$250M$0FY20FY21FY22FY23FY24FY25FY26
Show the numbers
YearFree cash flow
FY26−$758.6M
FY25−$844.1M
FY24−$766.7M
FY23−$856.1M
FY22−$695.2M
FY21−$557.9M
FY20-
Returned to shareholdersDividends paid and shares bought back
$0$500M$1B$1.5BFY20FY21FY22FY23FY24FY25FY26
Show the numbers
YearBuybacks
FY26-
FY25$1.3B
FY24$0
FY23$0
FY22-
FY21-
FY20-
Net margin vs the sectorMedian of Healthcare companies filing with the SEC
  • Roivant Sciences Ltd.
  • Healthcare median
−5000%0%5000%10000%15000%FY20FY21FY22FY23FY24FY25FY26
Show the numbers
YearRoivant Sciences Ltd.Healthcare median
FY26−3629.2%−11.1%
FY25−592%−30.6%
FY2413294.2%−47%
FY23−3200.2%−58%
FY22−1528.9%−80.4%
FY21−3400.9%−71.9%
FY20-−62.2%